阿霉素与米托蒽醌联合化疗对犬淋巴瘤疗效和毒性的比较
Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
作者信息
Wang Shang-Lin, Lee Jih-Jong, Liao Albert Taiching
机构信息
National Taiwan University Veterinary Hospital, College of Bioresources and Agriculture (Wang), Department and Graduate Institute of Veterinary Medicine, School of Veterinary Medicine (Wang, Liao), Graduate Institute of Veterinary Clinical Science, School of Veterinary Medicine (Lee), Animal Cancer Center, College of Bioresources and Agriculture (Lee, Liao), National Taiwan University, Taipei, 10672, Taiwan, Republic of China.
出版信息
Can Vet J. 2016 Mar;57(3):271-6.
Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol. There was no statistical difference in signalment and the presence of historical negative prognostic factors between the groups. The median progression-free survival (PFS) in the CHOP and CMOP groups were 222 d and 162 d, respectively (P = 0.75). The median survival time (MST) of dogs in CHOP and CMOP groups were 318 d and 242 d, respectively (P = 0.63). Anorexia and diarrhea episodes were significantly higher in the CHOP group than in the CMOP group (P = 0.02 and P = 0.01, respectively). These results suggest that the CMOP protocol provides similar PFS, MST and causes fewer side effects compared to the CHOP protocol. Therefore, the CMOP protocol may be another treatment choice for canine multicentric lymphoma.
44只患有多中心性淋巴瘤的犬只接受了环磷酰胺、阿霉素、长春新碱和泼尼松龙（CHOP）诱导方案治疗，或接受了环磷酰胺、米托蒽醌、长春新碱和泼尼松龙（CMOP）诱导方案治疗。两组之间在特征及既往不良预后因素的存在方面无统计学差异。CHOP组和CMOP组的无进展生存期（PFS）中位数分别为222天和162天（P = 0.75）。CHOP组和CMOP组犬只的中位生存时间（MST）分别为318天和242天（P = 0.63）。CHOP组的厌食和腹泻发作显著高于CMOP组（分别为P = 0.02和P = 0.01）。这些结果表明，与CHOP方案相比，CMOP方案提供了相似的PFS、MST，且副作用更少。因此，CMOP方案可能是犬多中心性淋巴瘤的另一种治疗选择。
Zotero 插件